<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dextromethorphan poisoning: Management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dextromethorphan poisoning: Management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Dextromethorphan poisoning: Management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Chris Rosenbaum, MD, MSc, FACEP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Edward W Boyer, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michele M Burns, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Evan Schwarz, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The management of <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">dextromethorphan</a> (DXM) poisoning will be reviewed here. The epidemiology, pertinent pharmacology, and clinical features of dextromethorphan poisoning are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6488.html" rel="external">"Dextromethorphan misuse and poisoning: Clinical features and diagnosis"</a>.)</p><p>Related issues such as methylenedioxymethamphetamine (MDMA) misuse, serotonin syndrome, anticholinergic (antimuscarinic) poisoning, <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> intoxication, phencyclidine (PCP) intoxication, ethanol intoxication, and a general approach to management of the poisoned patient are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/302.html" rel="external">"MDMA (ecstasy) intoxication"</a> and  <a class="medical medical_review" href="/z/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a> and  <a class="medical medical_review" href="/z/d/html/305.html" rel="external">"Anticholinergic poisoning"</a> and  <a class="medical medical_review" href="/z/d/html/298.html" rel="external">"Ketamine poisoning"</a> and  <a class="medical medical_review" href="/z/d/html/6506.html" rel="external">"Phencyclidine (PCP) intoxication in children and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/6487.html" rel="external">"Ethanol intoxication in children: Clinical features, evaluation, and management"</a> and  <a class="medical medical_review" href="/z/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6496.html" rel="external">"Approach to the child with occult toxic exposure"</a>.)</p><p class="headingAnchor" id="H1114943080"><span class="h1">CLINICAL FEATURES AND DIAGNOSIS</span><span class="headingEndMark"> — </span>The clinical features and diagnosis of <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">dextromethorphan</a> (DXM) poisoning are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6488.html" rel="external">"Dextromethorphan misuse and poisoning: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">SUPPORTIVE CARE</span><span class="headingEndMark"> — </span>Recommendations for care of children and adults with <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">dextromethorphan</a> (DXM) poisoning are derived from case series and reports and are driven by physical findings. The management of DXM poisoning is primarily supportive. (See  <a class="medical medical_review" href="/z/d/html/6488.html" rel="external">"Dextromethorphan misuse and poisoning: Clinical features and diagnosis", section on 'Clinical features'</a>.)</p><p>In addition, to careful assessment and support of airway, breathing, and circulation as needed, the clinician should anticipate and aggressively manage dissociative signs and symptoms (eg, psychosis, hallucinations, agitation), hyperthermia, rhabdomyolysis, and dehydration [<a href="#rid1">1-4</a>]. Specific antidotal therapy may be necessary for patients who manifest coma and respiratory depression, serotonin syndrome, or concomitant anticholinergic poisoning. (See <a class="local">'Naloxone (for respiratory depression and coma)'</a> below and <a class="local">'Management of potential co-ingestants'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h2">Restraint and sedation</span><span class="headingEndMark"> — </span>Early management of agitation or violent behavior is essential to prevent patient and staff injury. The emergency provider should exclude life-threatening hypoglycemia and hypoxia as contributing factors to agitation as soon as is safely possible. Verbal reassurance and placement of the patient in a calm, quiet, and subdued environment may suffice in the adolescent or adult with mild to moderate DXM intoxication.</p><p>In the markedly agitated or floridly psychotic patient, initial control often requires supine physical restraint that is rapidly followed by sedation with intravenous or intramuscular benzodiazepines (eg, <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> 0.1 mg/kg; maximum initial dose: 2 mg, repeat in 10 to 30 minutes as needed). Parenteral neuroleptic medication (eg, <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a>) should be avoided in patients with DXM overdose because it may exacerbate hyperthermia or anticholinergic symptoms. (See  <a class="medical medical_review" href="/z/d/html/291.html" rel="external">"Assessment and emergency management of the acutely agitated or violent adult"</a> and  <a class="medical medical_review" href="/z/d/html/6440.html" rel="external">"Emergency department approach to acute-onset psychosis in children", section on 'Patient and staff safety'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Hyperthermia</span><span class="headingEndMark"> — </span>Active cooling measures should be instituted promptly in patients with elevated rectal temperature and with other findings that indicate severe hyperthermia (eg, pulmonary edema, rhabdomyolysis). (See  <a class="medical medical_review" href="/z/d/html/176.html" rel="external">"Severe nonexertional hyperthermia (classic heat stroke) in adults", section on 'Diagnosis'</a>.)</p><p>Augmentation of evaporative cooling is considered the treatment of choice because it is effective, noninvasive, and easily performed. The naked patient is sprayed with a mist of lukewarm water while air is circulated with large fans. Shivering may be suppressed with intravenous benzodiazepines such as <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a> (5 mg IV) or <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> (1 to 2 mg IV). Cold inspired oxygen, cold gastric lavage, cooling blankets, and cold intravenous fluids may be helpful adjuncts. (See  <a class="medical medical_review" href="/z/d/html/176.html" rel="external">"Severe nonexertional hyperthermia (classic heat stroke) in adults", section on 'Management'</a> and  <a class="medical medical_review" href="/z/d/html/6596.html" rel="external">"Heat stroke in children", section on 'Rapid cooling'</a>.)</p><p>Some experts advocate that patients with marked hyperthermia (temperature &gt;40°C) might benefit from rapid sequence intubation followed by prolonged paralysis to stop heat generation from muscle activity.</p><p>There is NO ROLE for antipyretic agents such as <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> or <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> in the management of drug-induced hyperthermia, since the underlying mechanism does not involve a change in the hypothalamic temperature set-point. Alcohol sponge baths should also be avoided because large amounts of the isopropyl alcohol may be absorbed through dilated cutaneous vessels and produce toxicity.</p><p class="headingAnchor" id="H5"><span class="h2">Rhabdomyolysis</span><span class="headingEndMark"> — </span>Hyperthermia, agitation, seizures, and muscle rigidity may lead to muscle cell breakdown (rhabdomyolysis) with significant risk for renal failure. Patients with rhabdomyolysis typically present with the triad of pigmented granular casts in the urine, a red to brown color of the urine supernatant, and a marked elevation in the plasma concentration of creatine kinase (CK). Primary management goals consist of (see  <a class="medical medical_review" href="/z/d/html/14036.html" rel="external">"Prevention and treatment of heme pigment-induced acute kidney injury (including rhabdomyolysis)"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Fluid repletion with normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> infusion (20 to 40 mL/kg per hour up to 1 to 2 L per hour); the emergency provider should closely monitor urine output with the goal of maintaining a minimum urine flow of 4 mL/kg per hour; 200 mL per hour in adults. Once diuresis is established, alkalinization of the urine and <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">mannitol</a> diuresis is commonly employed but efficacy is uncertain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation for significant electrolyte abnormalities (hyperkalemia, hyperphosphatemia, and hypocalcemia); management of hyperkalemia is of particular importance. Hypocalcemia is usually transient and calcium administration should be avoided unless severe symptoms (eg, tetany) are present.</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Serotonin syndrome (serotonin toxicity)</span><span class="headingEndMark"> — </span>In addition to supportive care aimed at agitation and hyperthermia as described above, patients suspected of serotonin syndrome frequently require aggressive sedation with benzodiazepines  (<a class="graphic graphic_table graphicRef73400" href="/z/d/graphic/73400.html" rel="external">table 1</a>). In severe cases, serotonin receptor blockade with <a class="drug drug_general" data-topicid="9311" href="/z/d/drug information/9311.html" rel="external">cyproheptadine</a> may be indicated. (See  <a class="medical medical_review" href="/z/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a>.)</p><p class="headingAnchor" id="H4260151776"><span class="h2">Seizure</span><span class="headingEndMark"> — </span>Seizures are best managed with a benzodiazepine (eg, 0.1 mg/kg <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a>, maximum dose: 2 mg; repeat every 2 to 3 minutes up to three doses). <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">Phenobarbital</a> in an initial dose of 15 to 20 is preferred to <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> as second line treatment if seizures persist. (See  <a class="medical medical_review" href="/z/d/html/6192.html" rel="external">"Management of convulsive status epilepticus in children"</a> and  <a class="medical medical_review" href="/z/d/html/2217.html" rel="external">"Convulsive status epilepticus in adults: Classification, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">GASTROINTESTINAL DECONTAMINATION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">Dextromethorphan</a> (DXM) and other components of over-the-counter (OTC) cough medications bind well to activated charcoal (AC), the primary means of decontamination in overdose.</p><p>We suggest that patients who ingest DXM-containing medicines and who present within one hour of known or suspected ingestion receive AC (1 g/kg, maximum dose 50 g) by mouth or nasogastric tube. AC should be withheld in patients who are sedated and may not be able to protect their airway, unless tracheal intubation is performed first. However, tracheal intubation should <strong>not</strong> be performed solely for the purpose of giving AC. The greatest benefit occurs if AC is given within one hour. The efficacy of AC as a function of time from ingestion is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Evidence of efficacy and adverse effects'</a>.)</p><p>The recommendation for AC administration following DXM overdose derives from indirect evidence of benefit in volunteers, animal studies, and evidence of benefit following ingestions of other medications. Because of adverse effects, such as vomiting and dehydration, the combination of a cathartic (eg, <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">sorbitol</a>) and AC should be used sparingly, if at all, and only a single dose of a cathartic should be given to any patient. (See  <a class="medical medical_review" href="/z/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Activated charcoal'</a> and  <a class="medical medical_review" href="/z/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Cathartics'</a>.)</p><p>We recommend <strong>not</strong> performing gastric emptying by gastric lavage or by syrup of ipecac-induced emesis in patients who ingest DXM. This recommendation is based on randomized controlled trials showing minimal benefit and possible risk to patients who undergo gastric emptying after poisoning. (See  <a class="medical medical_review" href="/z/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient"</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">NALOXONE (FOR RESPIRATORY DEPRESSION AND COMA)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">Naloxone</a> administration has reversed respiratory depression and coma following <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">dextromethorphan</a> poisoning in some patients [<a href="#rid5">5-8</a>]. Patients with deep coma and respiratory depression should receive intravenous naloxone (0.1 mg/kg, maximum initial dose: 2 mg). Some patients may require total doses of naloxone approaching 10 mg to fully reverse symptoms of respiratory depression [<a href="#rid5">5</a>]. Patients who improve after naloxone administration still warrant hospital admission and intensive monitoring for recurrence of symptoms. (See  <a class="medical medical_review" href="/z/d/html/300.html" rel="external">"Acute opioid intoxication in adults", section on 'Basic measures and antidotal therapy'</a> and  <a class="medical medical_review" href="/z/d/html/6504.html" rel="external">"Opioid intoxication in children and adolescents", section on 'Naloxone'</a>.)</p><p><a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">Naloxone</a> administration should not delay the timely provision of supportive care (eg, bag-valve-mask ventilation) in patients who do not initially respond.</p><p class="headingAnchor" id="H9"><span class="h1">MANAGEMENT OF POTENTIAL CO-INGESTANTS</span><span class="headingEndMark"> — </span>In addition to <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">dextromethorphan</a> (DXM), over-the-counter cough formulations frequently contain other pharmaceutical agents whose toxicity may complicate DXM poisoning, such as <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, <a class="drug drug_general" data-topicid="8860" href="/z/d/drug information/8860.html" rel="external">chlorpheniramine</a> or other antihistamines, or <a class="drug drug_general" data-topicid="9833" href="/z/d/drug information/9833.html" rel="external">pseudoephedrine</a>.</p><p class="headingAnchor" id="H10"><span class="h2">Acetaminophen</span><span class="headingEndMark"> — </span>Patients with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentrations in the possible toxic range, based on the Rumack-Matthew nomogram  (<a class="graphic graphic_figure graphicRef83590" href="/z/d/graphic/83590.html" rel="external">figure 1</a>) should receive oral or intravenous antidote therapy with <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">N-acetylcysteine</a>. (See  <a class="medical medical_review" href="/z/d/html/340.html" rel="external">"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/318.html" rel="external">"Acetaminophen (paracetamol) poisoning: Management in adults and children"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Antihistamines</span><span class="headingEndMark"> — </span>DXM intoxication is frequently complicated by anticholinergic poisoning caused by coingestion of antihistamines in the cough and cold formulation. (See  <a class="medical medical_review" href="/z/d/html/16258.html" rel="external">"Over-the-counter cough and cold preparations: Approach to pediatric poisoning", section on 'Antihistamines'</a>.)</p><p>Both DXM and anticholinergic poisoning have similar presenting signs and symptoms that makes management decisions difficult. (See  <a class="medical medical_review" href="/z/d/html/6488.html" rel="external">"Dextromethorphan misuse and poisoning: Clinical features and diagnosis", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/6488.html" rel="external">"Dextromethorphan misuse and poisoning: Clinical features and diagnosis", section on 'Clinical features'</a>.)</p><p>Agitation and delirium caused by anticholinergic poisoning is initially treated with benzodiazepines (<a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> 0.1 mg; maximum dose: 2 mg). Some experts recommend that patients with anticholinergic poisoning manifesting both peripheral signs (eg, flushing, dry skin, hyperthermia) and central effects (agitated delirium, seizures) receive <a class="drug drug_general" data-topicid="9770" href="/z/d/drug information/9770.html" rel="external">physostigmine</a>. However, this recommendation is controversial and consultation with a medical toxicologist or regional poison center should be obtained before physostigmine is administered. (See  <a class="medical medical_review" href="/z/d/html/305.html" rel="external">"Anticholinergic poisoning"</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Phenylephrine and similar decongestants</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">Phenylephrine</a> and other alpha-1 adrenergic agonists can precipitate a hypertensive emergency in overdose that may require emergent administration of intravenous antihypertensive medication (eg, <a class="drug drug_general" data-topicid="9767" href="/z/d/drug information/9767.html" rel="external">phentolamine</a> 0.1 mg/kg; maximum dose: 5 mg). (See  <a class="medical medical_review" href="/z/d/html/3840.html" rel="external">"Drugs used for the treatment of hypertensive emergencies", section on 'Phentolamine'</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">DISPOSITION</span><span class="headingEndMark"> — </span>Most patients with uncomplicated <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">dextromethorphan</a> (DXM) poisoning have resolution of symptoms within four to six hours after ingestion [<a href="#rid9">9-11</a>]. Patients with complicated courses marked by hyperthermia, rhabdomyolysis, or serotonin syndrome warrant intensive care until symptoms resolve. (See <a class="local">'Supportive care'</a> above.)</p><p>Patients who are suicidal require psychiatric evaluation prior to discharge and should also be carefully evaluated for coingestions including the measurement of an <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration.</p><p>Patients who are asymptomatic for six hours after ingestion of DXM, who have nontoxic <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentrations, and who are not suicidal, may be discharged home.</p><p class="headingAnchor" id="H14"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H4121170298"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H1764034039"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112689.html" rel="external">"Society guideline links: General measures for acute poisoning treatment"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/114014.html" rel="external">"Society guideline links: Treatment of acute poisoning caused by specific agents other than drugs of abuse"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features and diagnosis</strong> – The clinical features and diagnosis of <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">dextromethorphan</a> (DXM) poisoning are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6488.html" rel="external">"Dextromethorphan misuse and poisoning: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive care</strong> – Management of DXM poisoning is primarily supportive. In addition, to careful assessment and support of airway, breathing, and circulation as needed, the clinician should anticipate and aggressively manage agitation, hyperthermia, rhabdomyolysis, and/or serotonin syndrome when they occur. (See <a class="local">'Supportive care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal decontamination</strong> – In a patient who ingests DXM-containing medicines and presents within one hour of known or suspected ingestion, we suggest administering activated charcoal (AC) (1 g/kg; maximum dose: 50 g) by mouth or nasogastric tube (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Charcoal should be withheld in patients who are sedated and may not be able to protect their airway, unless tracheal intubation is performed first. However, tracheal intubation should <strong>not</strong> be performed solely for the purpose of giving charcoal. (See <a class="local">'Gastrointestinal decontamination'</a> above.)</p><p></p><p class="bulletIndent1">In a patient with a DXM ingestion, we recommend against performing gastric emptying procedures (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Naloxone</strong> – Patients with deep coma and respiratory depression should receive intravenous <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> (0.1 mg/kg, maximum initial dose: 2 mg). Some patients may require total doses of naloxone approaching 10 mg to adequately reverse symptoms. Naloxone administration should not delay the timely provision of supportive care (eg, bag-valve-mask ventilation with 100 percent oxygen) in patients with respiratory depression. (See <a class="local">'Naloxone (for respiratory depression and coma)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential for co-ingestants</strong> – In addition to DXM, over-the-counter cough formulations frequently contain other pharmaceutical agents (eg, <a class="drug drug_general" data-topicid="8860" href="/z/d/drug information/8860.html" rel="external">chlorpheniramine</a> or other antihistamines, <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, <a class="drug drug_general" data-topicid="9833" href="/z/d/drug information/9833.html" rel="external">pseudoephedrine</a>) whose toxicity may complicate DXM poisoning and require specific treatment. (See <a class="local">'Management of potential co-ingestants'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kirages TJ, Sulé HP, Mycyk MB. Severe manifestations of coricidin intoxication. Am J Emerg Med 2003; 21:473.</a></li><li><a class="nounderline abstract_t">Graudins A, Fern RP. Acute dystonia in a child associated with therapeutic ingestion of a dextromethorphan containing cough and cold syrup. J Toxicol Clin Toxicol 1996; 34:351.</a></li><li><a class="nounderline abstract_t">Warden CR, Diekema DS, Robertson WO. Dystonic reaction associated with dextromethorphan ingestion in a toddler. Pediatr Emerg Care 1997; 13:214.</a></li><li><a class="nounderline abstract_t">Henretig F, Cugini D, Dubin D. Dextromethorphan overdose in children. Vet Hum Toxicol 1988; 3:364.</a></li><li><a class="nounderline abstract_t">Wolfe TR, Caravati EM. Massive dextromethorphan ingestion and abuse. Am J Emerg Med 1995; 13:174.</a></li><li><a class="nounderline abstract_t">Schneider SM, Michelson EA, Boucek CD, Ilkhanipour K. Dextromethorphan poisoning reversed by naloxone. Am J Emerg Med 1991; 9:237.</a></li><li><a class="nounderline abstract_t">Shaul WL, Wandell M, Robertson WO. Dextromethorphan toxicity: reversal by naloxone. Pediatrics 1977; 59:117.</a></li><li><a class="nounderline abstract_t">Kumar D, Shinde V, Khuraijam S, Puthoor A. Two Cases of Dextromethorphan Overdose Reversed by Naloxone. Cureus 2023; 15:e34501.</a></li><li><a class="nounderline abstract_t">Boyer EW. Dextromethorphan abuse. Pediatr Emerg Care 2004; 20:858.</a></li><li class="breakAll">Boyer E. Dissociative agents: Phencyclidine, ketamine, dextromethorphan. In: Haddad and Wincehster's Clinical Management of Poisoning and Drug Overdose, 4th, Shannon MW, Borron SW, Burns MJ (Eds), Saunders, Philadelphia 2007. p.776.</li><li><a class="nounderline abstract_t">LoVecchio F, Pizon A, Matesick L, O'Patry S. Accidental dextromethorphan ingestions in children less than 5 years old. J Med Toxicol 2008; 4:251.</a></li></ol></div><div id="topicVersionRevision">Topic 6492 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14574654" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Severe manifestations of coricidin intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8667476" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Acute dystonia in a child associated with therapeutic ingestion of a dextromethorphan containing cough and cold syrup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9220509" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Dystonic reaction associated with dextromethorphan ingestion in a toddler.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Dextromethorphan overdose in children</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7893303" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Massive dextromethorphan ingestion and abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2018593" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Dextromethorphan poisoning reversed by naloxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/840529" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Dextromethorphan toxicity: reversal by naloxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36874326" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Two Cases of Dextromethorphan Overdose Reversed by Naloxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15572980" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Dextromethorphan abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15572980" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Dextromethorphan abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19031376" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Accidental dextromethorphan ingestions in children less than 5 years old.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
